Epilepsy – Unmet Need – Detailed, Expanded Analysis : Dravet Syndrome: US/EU

Dravet syndrome (DS) is a rare, severe, pediatric-onset form of epilepsy characterized by developmental delay or regression and multiple types of difficult-to-treat seizures. Only a handful of antiepileptic drugs (AEDs), including Diacomit (stiripentol), Epidiolex / Epidyolex (cannabidiol), and Fintepla (fenfluramine), are approved for the adjunctive treatment of DS, but owing to various factors, off-label generic AEDs such as clobazam and valproate remain the first-line choice in DS treatment. Moreover, most patients do not achieve complete seizure control with currently available AEDs, even when prescribed concomitantly. Understanding the drivers of clinical decision-making in DS, prescribers’ perception of current treatment options, and areas of remaining unmet need will help drug developers identify levers to optimize the positioning and differentiation of new products.


  • What are the treatment drivers and goals for DS?
  • What attributes drive decision-making in DS, which have limited impact, and which are hidden opportunities?
  • How do approved agents (i.e., Diacomit, Epidiolex / Epidyolex, and Fintepla) perform on these attributes? How do key off-label AEDs (i.e., clobazam, topiramate, and valproate) perform on these attributes?
  • What are the prevailing areas of unmet need and opportunity in DS?
  • Based on a conjoint analysis and TPP simulation, what trade-offs across different clinical attributes and price are acceptable to neurologists for a hypothetical new DS drug?


Provides quantitative insight into U.S. and European physician perceptions of key treatment drivers and goals and the current level of unmet need for a specific disease. Commercial opportunities are analyzed, and the extent to which emerging therapies may capitalize on these opportunities is evaluated.

Markets covered: United States, United Kingdom, France, Germany

Primary research: Survey of 60 U.S. and 31 European neurologists fielded in January 2021

Key companies: Biocodex, GW Pharmaceuticals, Zogenix, Takeda, Zynerba Pharmaceuticals

Key drugs: Diacomit, Epidiolex / Epidyolex, Fintepla, clobazam, topiramate, valproate

Table of contents

launch Related Market Assessment Reports